This educational activity will explore the evolving issues, key questions and controversies associated with the use of immunotherapies for the treatment of patients with both solid tumor and hematologic malignancies. Discussion will include an overview of cancer immunobiology, types of available immunotherapy agents, current and expanding indications, evolving biomarkers and companion diagnostic testing, and management of immune-related adverse events. Patient cases will be used to highlight therapy selection as well as adverse effects and toxicity management strategies.
Agenda
Welcome and Introductions
Christine Walko, Pharm.D.
Current Immune Checkpoint Inhibitors and Mechanism of Action in Cancer Therapy
Christine Walko, Pharm.D.
Evolving Biomarkers and Companion Diagnostic Testing
Christine Walko, Pharm.D.
Patient Case-Initiating and Monitoring Immune Checkpoint Inhibitors
Ragini Kudchadkar, M.D.
Immuno-oncology Toxicity Recognition and Management
Ragini Kudchadkar, M.D.
Panel Discussion: Questions and Answers
Learning Objectives
- Identify the components of the human immune system and explain the mechanisms of action for using immune checkpoint inhibitors in cancer treatment.
- Examine the role of different companion diagnostic tests and interpret PD-L1 test results as they relate to selection of immune checkpoint inhibitor therapy.
- Analyze appropriate guidelines to guide management of common and less common immune related adverse effects from immune checkpoint inhibitors use.
- Formulate appropriate monitoring and management strategies for patients receiving immune checkpoint inhibitors.
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of cancer patients with immunotherapies.
Format
The activity features slide presentations, active learning, and questions/discussion with faculty.
Format
This online activity consists of slide presentations, active learning, and evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Christine M. Walko, Pharm.D., BCOP, FCCP
- Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board
Ragini R. Kudchadkar, M.D
- Array, Immunocore, Bristol-Myers Squibb: Advisory Board member
- Merck: Research funding received
Claim CE Within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-18-441-H01-P
Release Date: March 1, 2019
Expiration Date: May 22, 2020
Activity Type: Application-based
CE Credits: 1.5 hours
Activity Fee: Free of charge
CME INFORMATION
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
